Chronic kidney disease is well recognized to be a state of aberrant lipid metabolism and inflammation, both of which contribute to the cardiovascular morbidity and mortality encountered in this population. Even after successful renal transplantation, both dyslipidemia and the inflammatory milieu persist, and lead not only to premature atherosclerosis, but also to the development of chronic allograft nephropathy and eventual graft loss. The independent adverse effects of, and also the complex interplay between, dyslipidemia and inflammation on vascular health will be discussed in the first part of this chapter. The statins are a group of agents that have potent lipid lowering effects and are being used commonly in the post-transplant period. More recently, the statins have been demonstrated to have immunomodulatory effects independent of their lipid-lowering action. These immunologic effects of the statins may turn out to be of much greater significance for patients with CKD and those with transplants. The latter part of this chapter will address the clinical data demonstrating the beneficial effects of statins in transplant recipients and also discuss the mechanisms by which the statins might mediate these benefits.
|Original language||English (US)|
|Title of host publication||Progress in Kidney Transplantation Research|
|Publisher||Nova Science Publishers, Inc.|
|Number of pages||17|
|State||Published - 2006|
ASJC Scopus subject areas